Comparative Pharmacology
Head-to-head clinical analysis: CLINDA DERM versus CLINDAGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDA DERM versus CLINDAGEL.
CLINDA-DERM vs CLINDAGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by interfering with peptide chain formation. It has bacteriostatic activity against susceptible organisms.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, disrupting peptide chain initiation. It may also exhibit anti-inflammatory and immunomodulatory effects via inhibition of neutrophil chemotaxis and phagocytosis.
Topical: Apply a thin film to affected area twice daily. For acne vulgaris, available as 1% gel, lotion, or solution.
Apply thin layer to affected area twice daily.
None Documented
None Documented
2-4 hours (terminal half-life) in adults with normal renal function; prolonged in hepatic impairment (up to 8-12 hours) and severe renal impairment.
2-3 hours in patients with normal renal function; clinically significant accumulation may occur in severe hepatic impairment.
Primarily renal (10-20% unchanged; remainder as metabolites) and biliary/fecal (approximately 40-50% of dose as metabolites in feces).
Approximately 10% of the dose is excreted renally as unchanged drug; the remainder is hepatically metabolized and excreted in bile and feces. Renal clearance accounts for <1% of total clearance.
Category C
Category C
Topical Antibiotic
Topical Antibiotic